VolitionRx Secures Up to $2.3 Million in Latest Direct Offering Announcement

VolitionRx Limited (NYSE AMERICAN: VNRX), a leading multinational in the field of epigenetics, has announced the pricing of a new registered direct offering aimed at raising up to $2.3 million. The funding generates excitement as it is set to support the company’s vital research and product development initiatives.

On March 26, 2025, Volition disclosed definitive agreements to sell a total of 2,363,636 shares of its common stock to a designated group of insiders, including certain directors and executive officers. The shares will be sold at an offering price of $0.55 each. Additionally, 1,739,087 shares will be offered to both existing stockholders and new investors, paired with common stock purchase warrants, also priced at $0.55 each. This strategy enables VolitionRx to attract key investors while reinforcing the trust of its existing shareholder base.

Each common stock purchase warrant grants its holder the right to buy shares at $0.66 each. Warrants will remain exercisable immediately upon issuance, extending their validity for up to five years. Notably, insiders participating in the offering will not be entitled to purchase warrants, which is a strategic decision aimed at aligning offers to existing and new investors differently.

The expected closing date for the offering is set for March 26, 2025, pending satisfaction of standard closing conditions. The anticipated gross proceeds from this offering stand at around $2.3 million, not accounting for any expenses tied to the offering. If the warrants are fully exercised, an additional $1.1 million could potentially be raised, although the exercise of these warrants is not guaranteed.

VolitionRx plans to deploy the net proceeds to promote core areas such as research and product development, clinical studies, commercialization of their products, as well as general operational expenses. This move signals Volition’s commitment to expand its innovative capabilities in the healthcare sector, particularly focusing on diseases that significantly impact lives, including various forms of cancer and other critical health issues.

Currently headquartered in Henderson, Nevada, VolitionRx operates on an international scale with research and development primarily centered in Belgium, while also maintaining an innovation laboratory in the United States and an office in London. The company specializes in developing affordable and accessible blood tests aimed at detecting and monitoring various diseases at an early stage, thereby improving the quality of life for patients through timely interventions.

As a pioneer in the epigenetics domain, VolitionRx is dedicated to leveraging cutting-edge science to enhance health outcomes through early detection mechanisms. The announced direct offering not only reflects Volition's robust financial strategy but also underscores its efforts to pave the way for future advancements in the medical diagnostics arena.

With this funding effort, VolitionRx positions itself to push the frontiers of medical testing technology forward, making significant strides toward its mission of saving lives and enhancing healthcare delivery. Investors and healthcare professionals alike are watching the developments closely as VolitionRX charts its course in the evolving landscape of epigenetics and medical diagnostics.

For media inquiries, please contact Louise Batchelor at +44 (0)7557 774620. Investors are encouraged to reach out to Jeremy Feffer of LifeSci Advisors at +1-212-915-2568 for further information.

In a world increasingly defined by the urgency of healthcare innovations, VolitionRx's strategic moves are paving the way for significant advancements in disease detection and management.